The international firm is one of several pharmaceutical companies emphasizing new single-cell technologies to improve existing drugs and find new ones.
The deals cover Native Antigen's native and recombinant viral and bacterial antigens, antibodies, and immunoassays in certain European and Asian markets.
The firms will use AbCellera's antibody discovery platform, which combines a variety of technologies including next-generation sequencing and bioinformatics.
As part of the Human Vaccines Project, researchers sequenced samples from three adults and three infants to identify sets of shared and unique circulating B cell receptors.
The group this week published a set of initial guidelines for antibody validation meant as recommendations in advance of a larger meeting later this month.
The Hill reports 17 states and the District of Columbia are suing over a new policy that would strip international students of their visas if they only attend classes online.
The editorial board of the Pittsburgh Post-Gazette says other lawmakers should take Florida's approach and provide additional protections against genetic discrimination.
Centers for Disease Control and Prevention employees call on the agency to label racism a public health crisis and examine its own policies, NPR reports.
